Matthew Kirkpatrick to Administration, Intranasal
This is a "connection" page, showing publications Matthew Kirkpatrick has written about Administration, Intranasal.
Connection Strength
1.344
-
Effects of intranasal oxytocin on cigarette withdrawal and smoking in the laboratory: Differences by sex and social functioning traits. Exp Clin Psychopharmacol. 2024 Dec; 32(6):717-727.
Score: 0.850
-
Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology. 2014 Aug; 46:23-31.
Score: 0.105
-
Effects of MDMA and Intranasal oxytocin on social and emotional processing. Neuropsychopharmacology. 2014 Jun; 39(7):1654-63.
Score: 0.103
-
Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction. 2012 Apr; 107(4):783-91.
Score: 0.091
-
Effects of intranasal methamphetamine on metacognition of agency. Psychopharmacology (Berl). 2008 Mar; 197(1):137-44.
Score: 0.067
-
Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing. Neuropsychopharmacology. 2020 04; 45(5):823-832.
Score: 0.039
-
Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration. Psychoneuroendocrinology. 2016 12; 74:92-100.
Score: 0.031
-
Intranasal substituted cathinone "bath salts" psychosis potentially exacerbated by diphenhydramine. J Addict Med. 2013 May-Jun; 7(3):163-8.
Score: 0.025
-
Residual effects of intranasal methamphetamine on sleep, mood, and performance. Drug Alcohol Depend. 2008 Apr 01; 94(1-3):258-62.
Score: 0.017
-
Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology. 2008 Jul; 33(8):1847-55.
Score: 0.017